KRAS somatic mutations are found in 30-40% of colorectal cancer’s (CRC)1,2 and 10-30% of non-small cell lung carcinomas (NSCLC)3. Mutations have been reported in codons 12, 13, and 61, but a majority of these consist of six mutations in codon 12 (gly12ala, gly12asp, gly12arg, gly12cys, gly12ser, and gly12val) and one in codon 13 (gly13asp). Tumors with these mutations have been associated with poor responsiveness to anti-EGFR therapies 2,4-6.
Determining the KRAS status of a newly diagnosed NSCLC or CRC patient prior to initiating anti-EGFR therapy could be useful in selecting candidates for tyrosine kinase inhibitor (TKI) and monoclonal antibody (MAB) therapy, respectively. Additionally, testing could be considered for these individuals who are already on anti-EGFR therapy, but are demonstrating resistance.
To open a printable assay summary in a new window, click the link below.
KRAS Gene Mutation Analysis Assay Summary
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)
Please submit the Test Request Form (TRF) when ordering this test.
References
1. Lièvre, A. et al., (2008) J Clin Oncol; 26:374-9
2. Amado, R. G. et al., (2007) Eur J of Can Supp (5):6
3. Eberhard et al. (2005) J Clin Oncol; 23:5900-9
4. Di Fiore, F. et al., (2007) Br J Cancer; 96:1166-9
5. Han. et al., (2006) Clin Can Res; 12:2538-44
6. Pao. et al., (2005) PLoS Med; 2:e17
Back to the List of Services